Alexander Levitzki
Alexander Levitzki
Verifierad e-postadress på - Startsida
TitelCiteras avÅr
Tyrosine kinase inhibition: an approach to drug development
A Levitzki, A Gazit
Science 267 (5205), 1782-1788, 1995
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
R Catlett-Falcone, TH Landowski, MM Oshiro, J Turkson, A Levitzki, ...
Immunity 10 (1), 105-115, 1999
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
N Meydan, T Grunberger, H Dadi, M Shahar, E Arpaia, Z Lapidot, ...
Nature 379 (6566), 645, 1996
Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells
R Garcia, TL Bowman, G Niu, H Yu, S Minton, CA Muro-Cacho, CE Cox, ...
Oncogene 20 (20), 2499, 2001
EGF induces tyrosine phosphorylation of phospholipase C-II: a potential mechanism for EGF receptor signaling
B Margolis, SG Rhee, S Felder, M Mervic, R Lyall, A Levitzki, A Ullrich, ...
Cell 57 (7), 1101-1107, 1989
Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors
A Gazit, P Yaish, C Gilon, A Levitzki
Journal of medicinal chemistry 32 (10), 2344-2352, 1989
Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors
P Yaish, A Gazit, C Gilon, A Levitzki
Science 242 (4880), 933-935, 1988
ROS, stress‐activated kinases and stress signaling in cancer
M Benhar, D Engelberg, A Levitzki
EMBO reports 3 (5), 420-425, 2002
Transglutaminase is essential in receptor-mediated endocytosis of α2-macroglobulin and polypeptide hormones
PJA Davies, DR Davies, A Levitzki, FR Maxfield, P Milhaud, ...
Nature 283 (5743), 162, 1980
Negative cooperativity in regulatory enzymes
A Levitzki, DE Koshland
Proceedings of the National Academy of Sciences 62 (4), 1121-1128, 1969
Crystal structure of Hck in complex with a Src family–selective tyrosine kinase inhibitor
T Schindler, F Sicheri, A Pico, A Gazit, A Levitzki, J Kuriyan
Molecular cell 3 (5), 639-648, 1999
Mode of coupling between the β-adrenergic receptor and adenylate cyclase in turkey erythrocytes
AM Tolkovsky, A Levitzki
Biochemistry 17 (18), 3795-3810, 1978
Flk-1 as a target for tumor growth inhibition
LM Strawn, G McMahon, H App, R Schreck, WR Kuchler, MP Longhi, ...
Cancer Research 56 (15), 3540-3545, 1996
Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors
A Novogrodsky, A Vanichkin, M Patya, A Gazit, N Osherov, A Levitzki
Science 264 (5163), 1319-1322, 1994
Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases
M Nagane, A Levitzki, A Gazit, WK Cavenee, HJS Huang
Proceedings of the National Academy of Sciences 95 (10), 5724-5729, 1998
Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction.
A Levitzki
The FASEB Journal 6 (14), 3275-3282, 1992
Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to …
M Benhar, I Dalyot, D Engelberg, A Levitzki
Molecular and cellular biology 21 (20), 6913-6926, 2001
The effect of tyrosine‐specific protein phosphorylation on the assembly of adherens‐type junctions.
T Volberg, Y Zick, R Dror, I Sabanay, C Gilon, A Levitzki, B Geiger
The EMBO Journal 11 (5), 1733-1742, 1992
Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation
M Kovalenko, A Gazit, A Böhmer, C Rorsman, L Rönnstrand, CH Heldin, ...
Cancer Research 54 (23), 6106-6114, 1994
Epidermal‐growth‐factor‐dependent activation of the Src‐family kinases
N Osherov, A Levitzki
European journal of biochemistry 225 (3), 1047-1053, 1994
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20